Trump’s Rhetorical Pivot On Pharma: The Hucksterism Is Still A Threat
Executive Summary
It is nice for pharma CEOs to be called ‘brilliant’ by a President who once said they are ‘getting away with murder.’ But the ‘new’ Trump rhetoric still has major pitfalls for industry – including a fundamental risk of undermining regulatory standards.
You may also be interested in...
Republicans Favor Regulatory ‘Leeway’ On Drug Use During Emergencies, Bright Hearing Shows
In a Congressional hearing reminiscent of the right-to-try law debates, Democrats praised ousted BARDA Director Rick Bright for whistleblowing on the political interference in COVID-19 drug decisions, while Republicans argued the government should lower its standards during a pandemic and permit more widespread use of experimental medicines prior to clinical data.
Supply Chain Truce In COVID-19: Will It Carry Over When Rx Price Debate Resumes?
Manufacturers, insurers, pharmacies and PBMs are united in trying to assure ongoing access to medicines amid the COVID-19 outbreak. Will making common cause in a national emergency mean a more cooperative approach to addressing US drug pricing concerns when normalcy returns?
Vaccine Experts Inject Realism Into US Gov't's COVID-19 Timeline
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.